| Schedule of Related Party Transactions |
| |
|
|
|
|
|
|
| |
|
Year Ended March 31,
2016
($) |
|
|
Year Ended March 31,
2015
($) |
|
| Balance due from Pharma and NDM at beginning of period |
|
|
192,517 |
|
|
|
- |
|
| Amounts advanced to Pharma |
|
|
58,197 |
|
|
|
567,633 |
|
| Amounts received from Pharma |
|
|
(228,361 |
) |
|
|
(7,692 |
) |
| Reduction in prepayments to Pharma for clinical trials |
|
|
(247,596 |
) |
|
|
(257,441 |
) |
| Amounts invoiced by Pharma to DDL and TCL |
|
|
(331,714 |
) |
|
|
(106,193 |
) |
| Amounts invoiced by DDL to Pharma |
|
|
16,307 |
|
|
|
- |
|
| Expenses paid by Pharma on behalf of DDL and TCL |
|
|
- |
|
|
|
134 |
|
| Intellectual property costs paid by Pharma on behalf of DDL and TCL |
|
|
- |
|
|
|
(946 |
) |
| Sale of fixed and intangible assets to Pharma and NDM |
|
|
17,775 |
|
|
|
- |
|
| Foreign exchange differences |
|
|
28,763 |
|
|
|
(2,988 |
) |
| Net balance due to Pharma and NDM at end of the period |
|
|
(494,112 |
) |
|
|
192,517 |
|
|